Antibody-Catch technology platform - GRS-044/15
Third-party funded project
Project title Antibody-Catch technology platform - GRS-044/15
Principal Investigator(s) Ernst, Beat
Co-Investigator(s) Herrendorff, Ruben
Organisation / Research unit Departement Pharmazeutische Wissenschaften / Molekulare Pharmazie (Ernst)
Project start 01.03.2016
Probable end 01.03.2018
Status Completed
The goal of this project is to establish and validate a drug discovery platform, potentially enabling promising new personalized therapies in antibody-mediated autoimmune conditions. Platform-derived drugs are glycopolymers which selectively eliminate pathogenic autoantibodies in vivo. The new therapeutic concept with glycopolymers will be tested in autoimmune neuropathies, particularly in anti-MAG neuropathy, multifocal motor neuropathy, and Guillain-Barré syndrome.
Keywords Autoimmune neuropathies, autoantibodies, glycopolymers
Financed by Foundations and Associations

MCSS v5.8 PRO. 0.481 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |